Ovarian Cancer Drugs - Global Strategic Business Report

The global market for Ovarian Cancer Drugs was estimated at US$3.7 Billion in 2024 and is projected to reach US$4.8 Billion by 2030, growing at a CAGR of 4.5% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Ovarian Cancer Drugs market.

Global Ovarian Cancer Drugs Market - Key Trends and Drivers Summarized

Ovarian cancer is one of the most challenging gynecological cancers to treat due to its typically late diagnosis and the complexity of its progression. The primary treatment modalities for ovarian cancer include surgery, chemotherapy, targeted therapy, and, more recently, immunotherapy. Traditional chemotherapy, involving drugs such as paclitaxel and carboplatin, remains a cornerstone of treatment, often administered after surgical debulking to eliminate residual cancer cells. These drugs, while effective, come with significant side effects and the risk of developing drug resistance over time. Targeted therapies have emerged as a significant advancement in the treatment of ovarian cancer, with drugs like bevacizumab (an angiogenesis inhibitor) and PARP inhibitors (such as olaparib, niraparib, and rucaparib) offering more tailored approaches. These therapies specifically target cancer cell mechanisms, providing benefits in terms of efficacy and reduced toxicity compared to traditional chemotherapy.

The advent of targeted therapies has revolutionized the landscape of ovarian cancer treatment. PARP inhibitors, in particular, have shown remarkable success in patients with BRCA1 or BRCA2 mutations, as well as in those with homologous recombination deficiency (HRD). These drugs work by exploiting the DNA repair weaknesses in cancer cells, leading to cell death while sparing normal cells. Bevacizumab, on the other hand, inhibits the growth of blood vessels that supply the tumor, effectively starving the cancer cells. Additionally, immunotherapy is making strides with agents like pembrolizumab showing promise in clinical trials. Despite these advancements, the management of ovarian cancer remains complex, with a high recurrence rate necessitating ongoing treatment and monitoring. Research continues to focus on understanding the molecular and genetic underpinnings of the disease to develop more effective and personalized treatment options.

The growth in the ovarian cancer drugs market is driven by several factors. Increasing awareness and early diagnosis through advanced screening techniques are expanding the patient pool eligible for treatment. Technological advancements in genomics and molecular biology are facilitating the development of targeted therapies and personalized medicine, which are proving to be more effective and have fewer side effects. The substantial investment in research and development by pharmaceutical companies is leading to a robust pipeline of new drugs and combination therapies. Regulatory incentives and expedited approval processes for drugs targeting rare and aggressive cancers are also propelling market growth. Additionally, the rising incidence of ovarian cancer globally, coupled with an aging population, is increasing the demand for effective treatments. Collaborations between academic institutions, research organizations, and pharmaceutical companies are fostering innovation and expediting the translation of research into clinical practice. As these trends continue to evolve, the ovarian cancer drugs market is poised for significant growth, driven by the need for better therapeutic options and the ongoing advancements in cancer treatment.

SCOPE OF STUDY:

The report analyzes the Ovarian Cancer Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments: Therapy (Targeted Therapy, Hormonal Therapy, Chemotherapy, Radiation Therapy); End-Use (Hospital Pharmacies End-Use, Retail Pharmacies End-Use, Online Pharmacies End-Use)
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

Market Growth: Understand the significant growth trajectory of the Targeted Therapy segment, which is expected to reach US$2.9 Billion by 2030 with a CAGR of a 5.5%. The Hormonal Therapy segment is also set to grow at 3.7% CAGR over the analysis period.
Regional Analysis: Gain insights into the U.S. market, valued at $990.4 Million in 2024, and China, forecasted to grow at an impressive 7.7% CAGR to reach $991.3 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

Detailed Market Analysis: Access a thorough analysis of the Global Ovarian Cancer Drugs Market, covering all major geographic regions and market segments.
Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Ovarian Cancer Drugs Market.
Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

How is the Global Ovarian Cancer Drugs Market expected to evolve by 2030?
What are the main drivers and restraints affecting the market?
Which market segments will grow the most over the forecast period?
How will market shares for different regions and segments change by 2030?
Who are the leading players in the market, and what are their prospects?

Report Features:

Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
Company Profiles: Coverage of players such as AbbVie, Inc., Acrivon Therapeutics, AstraZeneca PLC, Bristol-Myers Squibb Company, Daiichi Sankyo Co., Ltd. and more.
Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 86 companies featured in this Ovarian Cancer Drugs market report include:

AbbVie, Inc.
Acrivon Therapeutics
AstraZeneca PLC
Bristol-Myers Squibb Company
Daiichi Sankyo Co., Ltd.
F. Hoffmann-La Roche AG
GSK PLC
ImmunoGen, Inc.
Imvax
Merck & Co., Inc.
Ono Pharmaceutical Co., Ltd.
Pfizer, Inc.
Taiho Pharmaceutical Co., Ltd.
Vivesto AB
Zymeworks, Inc.

This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:

Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.

I. METHODOLOGYII. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Influencer Market Insights
Global Economic Update
Ovarian Cancer Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

Increasing Awareness and Early Diagnosis Expand Addressable Market Opportunity
Advances in Genomic and Molecular Biology Propel Development of Targeted Therapies
Rising Incidence of Ovarian Cancer Drives Demand for Effective Treatments
Development of Personalized Medicine Strengthens Business Case for Novel Therapies
Growing Adoption of PARP Inhibitors and Other Targeted Therapies Spurs Market Expansion
Integration of Immunotherapy in Treatment Protocols Throws Spotlight on Innovative Approaches
Expansion of Clinical Trials for Combination Therapies Drives Market Growth
Enhanced Screening Techniques and Diagnostic Tools Accelerate Early Detection
Rising Healthcare Expenditure and Improved Access to Treatments Expand Market Reach
Growing Focus on Reducing Side Effects and Improving Quality of Life Propels Demand for Advanced Therapies
Focus on Overcoming Drug Resistance Generates Opportunities for New Treatments
Market Penetration in Emerging Economies Propels Growth

4. GLOBAL MARKET PERSPECTIVE

TABLE 1: World Ovarian Cancer Drugs Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 3: World Historic Review for Ovarian Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 4: World 15-Year Perspective for Ovarian Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 6: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 7: World 15-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 9: World Historic Review for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 10: World 15-Year Perspective for Hormonal Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 12: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 13: World 15-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 15: World Historic Review for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 16: World 15-Year Perspective for Radiation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Hospital Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 18: World Historic Review for Hospital Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 19: World 15-Year Perspective for Hospital Pharmacies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Retail Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 21: World Historic Review for Retail Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 22: World 15-Year Perspective for Retail Pharmacies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Online Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 24: World Historic Review for Online Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 25: World 15-Year Perspective for Online Pharmacies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

UNITED STATES
Ovarian Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 26: USA Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 27: USA Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 28: USA 15-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2015, 2025 & 2030
TABLE 29: USA Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 30: USA Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 31: USA 15-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
CANADA
TABLE 32: Canada Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 33: Canada Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 34: Canada 15-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2015, 2025 & 2030
TABLE 35: Canada Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 36: Canada Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 37: Canada 15-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
JAPAN
Ovarian Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 38: Japan Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 39: Japan Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 40: Japan 15-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2015, 2025 & 2030
TABLE 41: Japan Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 42: Japan Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 43: Japan 15-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
CHINA
Ovarian Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 44: China Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 45: China Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 46: China 15-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2015, 2025 & 2030
TABLE 47: China Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 48: China Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 49: China 15-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
EUROPE
Ovarian Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 50: Europe Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 51: Europe Historic Review for Ovarian Cancer Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 52: Europe 15-Year Perspective for Ovarian Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
TABLE 53: Europe Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 54: Europe Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 55: Europe 15-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2015, 2025 & 2030
TABLE 56: Europe Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 57: Europe Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 58: Europe 15-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
FRANCE
Ovarian Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 59: France Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 60: France Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 61: France 15-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2015, 2025 & 2030
TABLE 62: France Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 63: France Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 64: France 15-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
GERMANY
Ovarian Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 65: Germany Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 66: Germany Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 67: Germany 15-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2015, 2025 & 2030
TABLE 68: Germany Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 69: Germany Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 70: Germany 15-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
ITALY
TABLE 71: Italy Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 72: Italy Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 73: Italy 15-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2015, 2025 & 2030
TABLE 74: Italy Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 75: Italy Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 76: Italy 15-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
UNITED KINGDOM
Ovarian Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 77: UK Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 78: UK Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 79: UK 15-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2015, 2025 & 2030
TABLE 80: UK Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 81: UK Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 82: UK 15-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
SPAIN
TABLE 83: Spain Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 84: Spain Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 85: Spain 15-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2015, 2025 & 2030
TABLE 86: Spain Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 87: Spain Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 88: Spain 15-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
RUSSIA
TABLE 89: Russia Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 90: Russia Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 91: Russia 15-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2015, 2025 & 2030
TABLE 92: Russia Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 93: Russia Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 94: Russia 15-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
REST OF EUROPE
TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 96: Rest of Europe Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 97: Rest of Europe 15-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2015, 2025 & 2030
TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 99: Rest of Europe Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 100: Rest of Europe 15-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
ASIA-PACIFIC
Ovarian Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 102: Asia-Pacific Historic Review for Ovarian Cancer Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 103: Asia-Pacific 15-Year Perspective for Ovarian Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 105: Asia-Pacific Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 106: Asia-Pacific 15-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2015, 2025 & 2030
TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 108: Asia-Pacific Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 109: Asia-Pacific 15-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
AUSTRALIA
Ovarian Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
INDIA
Ovarian Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
SOUTH KOREA
REST OF ASIA-PACIFIC
LATIN AMERICA
Ovarian Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
ARGENTINA
BRAZIL
MEXICO
REST OF LATIN AMERICA
MIDDLE EAST
Ovarian Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
IRAN
ISRAEL
SAUDI ARABIA
UNITED ARAB EMIRATES
REST OF MIDDLE EAST
AFRICA
Ovarian Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

AbbVie, Inc.
Acrivon Therapeutics
AstraZeneca PLC
Bristol-Myers Squibb Company
Daiichi Sankyo Co., Ltd.
F. Hoffmann-La Roche AG
GSK PLC
ImmunoGen, Inc.
Imvax
Merck & Co., Inc.
Ono Pharmaceutical Co., Ltd.
Pfizer, Inc.
Taiho Pharmaceutical Co., Ltd.
Vivesto AB
Zymeworks, Inc.

Table Information

Report Attribute	Details
No. of Pages	250
Published	June 2025
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 3.7 Billion
Forecasted Market Value ( USD ) by 2030	$ 4.8 Billion
Compound Annual Growth Rate	4.5%
Regions Covered	Global

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€5255EUR$5,850USD£4,487GBP
1 - 10 USER LICENSE PDF	The product is a PDF.	This is a 1-10 user license, allowing up to ten users have access to the product.	€9984EUR$11,115USD£8,525GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€15764EUR$17,550USD£13,461GBP

Global Ovarian Cancer Drugs Market - Key Trends and Drivers Summarized

SCOPE OF STUDY:

Key Insights:

Why You Should Buy This Report:

Key Questions Answered:

Report Features:

Some of the 86 companies featured in this Ovarian Cancer Drugs market report include:

This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:

Table of Contents

Companies Mentioned (Partial List)

Table Information

Related Topics

Related Reports

Ovarian Cancer Drugs Market by Brand Type, Route of Administration, End User, Drug Class, Distribution Channel, Mechanism of Action, Line of Therapy - Global Forecast to 2030

United States Ovarian Cancer Therapeutics Market, Competition, Forecast & Opportunities, 2028

Doxorubicin Market Report 2025

Doxorubicin - Global Strategic Business Report

Ovarian Cancer Drugs Market Report 2025